Roche announces positive top-line Enspryng Phase III results from the METEOROID study, demonstrating a significant delay in relapses for patients with MOGAD.
Pfizer and Merck announce that the FDA has accepted a supplemental Biologics License Application (sBLA) for PADCEV in combination with KEYTRUDA for Priority Review in patients with muscle-invasive bladder cancer (MIBC).
AstraZeneca has announced that the Phase III MIRANDA trial for tozorakimab successfully met its primary endpoint, marking the third positive pivotal study for the IL-33-targeting biologic in patients with COPD.
Abbott (NYSE: ABT) has released its first-quarter 2026 financial results, showcasing strong organic growth and the strategic integration of Exact Sciences into its world-leading diagnostics portfolio.
Eli Lilly’s latest Phase 3 study, ACHIEVE-4, demonstrates that the oral GLP-1 Foundayo (orforglipron) provides significant cardiovascular protection, weight loss, and glycemic control for adults with type 2 diabetes.
GSK has finalized its $950 million acquisition of 35Pharma Inc., securing HS235 a potential best-in-class treatment for pulmonary hypertension with unique metabolic benefits.
Novo Nordisk and OpenAI have announced a historic strategic collaboration to integrate generative AI across R&D, manufacturing, and global operations to bring life-saving treatments to market faster.
Johnson & Johnson delivers a robust start to the year with the Johnson & Johnson Q1 2026 Results, reporting $24.1 billion in revenue and increasing its full-year earnings guidance amid major clinical approvals.
Topline results from the Phase 3 BRUIN CLL-322 trial confirm that Jaypirca significantly extended progression-free survival when added to a venetoclax regimen.
GSK has reached a major milestone with the NMPA’s Exdensur depemokimab China approval. This ultra-long-acting biologic offers a breakthrough for severe asthma patients, requiring only two doses per year to maintain symptom control.
